21st North Inc. Stock Analysis ULGX
Urologix, Inc. develops, manufactures, markets, and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia. The company is headquartered in Minneapolis, Minnesota and currently employs 61 full-time employees. The firm is engaged in providing a range of services and project management for the mineral industry. The company offers its clients multidisciplinary solutions combining geological knowledge with the latest exploration tools. Its services include office services and data management, and contract exploration. Its office services and data management services include property appraisal and independent valuations, report writing and resource compilations, exploration strategy, target generation and development, and outlining and supervision of metallurgical test work programs. Its contract exploration services include geological prospecting, exploration and mapping, project management / site management and geological staffing, and supervision and management of ground/airborne geophysical surveys.
Read More 21st North Inc (ULGX) Chart
Key Statistics of 21st North Inc (ULGX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.00Volume
125.00P/E Ratio (TTM)
-52 Week Range
Market Cap
2181.80Avg. Volume
16.11KDividend Yield
-Financial Metrics & Statements of 21st North Inc (ULGX)
FAQ's for 21st North Inc (ULGX)
- According to Musaffa’s Shariah screening methodology, 21st North Inc (ULGX) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.